Kephera Diagnostics announced the launch of EndomTest, the first non-invasive commercially available diagnostic test for endometriosis in the United States. This test only requires a blood sample.
Backed by over a decade of academic research and offered by Kephera under exclusive license from Exeltis, EndomTest measures two biomarkers, combining results with clinical variables using an algorithm that provides a rule-in diagnostic tool. Published clinical validation studies demonstrate 100% specificity, or no false positives, for this methodology. The test offers patients and providers reliable diagnostic results through a non-surgical approach, which can inform treatment decisions including the need for eventual surgery.
